Key Takeaways
- Lupin Pharmaceuticals has recalled two batches of its Tydemy birth control pills after reporting defects
- The company’s earnings beat reported higher profits and revenues
- Lupin’s share price rose 4% at the earnings news and has increased 47% in 2023
One of the most prominent players in the U.S. pharmaceutical industry has had to recall two batches of its birth control pills after finding they were defective. Lupin Pharmaceuticals has asked any retailers and distributors of Tydemy to stop selling the bad batches immediately and has advised those taking the pills to seek medical advice.
Despite the hiccup, Lupin’s earnings beat was enough to keep investors on side, and the share price saw a lift. Indian pharmaceuticals have outpaced their U.S. peers on the markets so far in 2023 – let’s take a look at the details.
Support authors and subscribe to content
This is premium stuff. Subscribe to read the entire article.
Login if you have purchased